CapsoVision (CV) announced that it has submitted an application to the FDA on November 6, requesting breakthrough device designation to accelerate development of the company’s CapsoCam UGI capsule endoscopy system for use in early-stage pancreatic cancer detection.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CV: